Churchill Pharmaceuticals, LLC (Churchill) a privately held company, is devoted to expanding treatments in cancer care by developing quality orally delivered oncology products with clinical profiles addressing efficacy, safety and efficiency. Churchill’s commitment to responsibly deliver these products to the patients, payers and healthcare communities we serve is at the core of its business. Churchill’s lead product, YONSA™ (abiraterone acetate) ultramicrosize tablets, has been accepted for filing by the U.S. Food and Drug Administration (FDA) in 2017. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of March 19, 2018 to complete its review. Yonsa™ has a significantly improved profile over the existing marketed product, which is very poorly dissolved in the body and exhibits very high variability such that many patients do not receive a consistent dose of this life saving drug. Product launch is planned for 2018.